サンプル依頼リスト カート
  • English
表紙：がん治療の日本市場の評価：用途別、治療法別、売れ筋医薬品別、エンドユーザー別、地域別、機会、予測（2017年度～2031年度）
市場調査レポート
商品コード
1355011

がん治療の日本市場の評価：用途別、治療法別、売れ筋医薬品別、エンドユーザー別、地域別、機会、予測（2017年度～2031年度）

Japan Cancer Therapeutics Market Assessment, By Applications, By Therapeutics, By Top Selling Drugs, By End-user, By Region, By Opportunities and Forecast, FY2017-FY2031F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 108 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
がん治療の日本市場の評価：用途別、治療法別、売れ筋医薬品別、エンドユーザー別、地域別、機会、予測（2017年度～2031年度）
出版日: 2023年10月02日
発行: Market Xcel - Markets and Data
ページ情報: 英文 108 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

日本のがん治療の市場規模は、2023年度に102億米ドル、2031年度に199億米ドルに達し、2024年度～2031年度の予測期間にCAGRで8.7%の成長が予測されています。がん罹患率の増加、がん治療に対する需要の向上、政府による力強い支援、製薬企業の強固なプレゼンス、日本の高齢化、生活習慣に関連するがんの増加、遠隔医療や遠隔患者モニタリングの利用の増加などの要因が、市場を前進させています。これらの要因は総体的に市場のダイナミックな成長に寄与しており、がん患者に病院や診療所の受診の必要性を減らしながら、より充実した治療へのアクセスを提供しています。

市場は医療の進歩をリードしており、そのダイナミックな分野を定義する重大な要因の集結によって形成されています。こうした要因の中でも、日本におけるがんの罹患率の増加は、革新的な治療法の差し迫った必要性を強調しています。日本が高齢化社会と取り組む中で、がんの罹患率は急上昇しており、診断、治療、患者のケアを含む包括的なアプローチが必要とされています。市場は、効果的ながん治療に対する需要の高まりによってさらに牽引されています。患者や医療プロバイダーは、人々に影響を及ぼす多様ながんと闘うために、最先端の治療法を積極的に求めています。

日本政府が果たす極めて重要な役割は、市場の成長に不可欠です。日本政府は、その政策、資金提供、取り組みを通じて、がん研究、早期発見、治療法の進歩に多大な支援を提供しています。国内外の影響力のある製薬企業のプレゼンスは、市場の活性化に大きく貢献しています。これらの企業は、先駆的な研究開発の最前線に立ち、革新的な治療法や治療オプションを世に送り出しています。さらに、生活習慣に関連したがんの罹患率の増加は、個別化された介入と治療の必要性を際立たせています。遠隔医療と遠隔患者モニタリングの採用は勢いを増しており、患者にアクセスしやすく便利な選択肢を提供することで、がん治療の提供に革命をもたらしています。このようなダイナミックな状況において市場は、がんと闘い、この手ごわい疾患に罹患した人々のウェルビーイングを向上させるというコミットメントを体現しています。

寿命の延長

寿命の延長は医療、ライフスタイルの改善、社会状況の進歩を意味し、がんに対する感受性の高まりを伴います。環境毒素や遺伝的変異などの危険因子への曝露は、時間の経過とともに増加します。その結果、人々が長寿を享受するにつれてがんの有病率が上昇し、死亡率の上昇に寄与しています。全人口におけるがん関連死亡の増加は、日本における顕著な動向である平均寿命の伸びに起因しています。この動向は、高齢者の割合の増加を特徴とする日本の急速な高齢化から生じています。2022年、日本の平均寿命は84.91歳となり、前年比で0.14％伸びました。この平均寿命の大幅な伸びは、がん患者の大幅な増加につながり、市場の需要拡大を促進しています。

政府の取り組み

日本の政府は、がん研究部門における重要な取り組みの推進において主導的な役割を果たしており、このことは市場にとって大きな支えとなっています。国民が抱えるがんに関連した課題への対処が急務であることを認識した日本は、この部門の進歩を推進するために多額のリソースを割り当て、多大な努力を払ってきました。こうした取り組みには、革新的な研究プロジェクトへの資金提供、学術機関と医療機関の連携の促進、国家的ながん対策プログラムの実施など、幅広い活動が含まれます。がん研究に対する政府の積極的な取り組みは、医療の成果を改善し、国民の全般的な健康とウェルビーイングを向上させるというコミットメントを示しています。

免疫療法への関心の高まり

免疫療法は、市場にとって有益ながん治療法として、顕著な需要の増加を示しています。その魅力の向上には複数の要因があります。まず、免疫療法は特定のがん種で顕著な効果を示し、持続的な治療効果をもたらすことが多いです。さらに、日本の医療制度が技術革新、徹底した臨床試験、承認手続きに専念しているため、最先端の免疫療法が医療市場に統合され、患者のアクセスが向上しています。

当レポートでは、日本のがん治療市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 日本のがん治療薬市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 日本のがん治療市場の見通し（2017年度～2031年度）

  • 市場規模と予測
    • 金額
    • 数量
  • 用途別
    • 肺がん
    • 血液がん
    • 大腸がん
    • 前立腺がん
    • 乳がん
    • 子宮頸がん
    • 膠芽腫
    • 頭頸部がん
    • 悪性髄膜腫
    • 中皮腫
    • 黒色腫
    • その他
  • 治療法別
    • 化学療法
    • 標的療法
    • 免疫療法
    • ホルモン療法
    • その他
  • 売れ筋医薬品別
    • レブラミド
    • アバスチン
    • ハーセプチン
    • リツキサン
    • オプジーボ
    • グリベック
    • ベルケイド
    • インブルヴィカ
    • イブランス
    • ザイティガ
    • アリムタ
    • シュタンディ
    • タルセバ
    • パージェタ
    • テモダル
    • その他
  • エンドユーザー別
    • 病院
    • 専門クリニック
    • がん・放射線治療
  • 地域別
    • 北部（北海道、東北）
    • 中部（関東、中部）
    • 南部（関西、中国、四国、九州、沖縄）
  • 市場シェア：企業別（2023年度）

第6章 市場マッピング（2023年度）

  • 用途別
  • 治療法別
  • 売れ筋医薬品別
  • エンドユーザー別
  • 地域別

第7章 マクロ環境と産業構造

  • 需給分析
  • 輸出入の分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

  • 臨床試験
  • 特許の情勢
  • 規制当局の承認
  • イノベーション/最新技術

第10章 主要企業の情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益の分析（2023年度）
  • 合併と買収/合弁事業（該当する場合）
  • SWOT分析（市場参入企業5社向け）
  • 特許分析（該当する場合）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • Daiichi Sankyo Company, Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Chugai Pharmaceutical Co., Ltd.
  • Astellas Pharma Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • Shionogi & Co., Ltd.
  • Kyowa Kirin Co., Ltd.
  • Ono Pharmaceutical Co., Ltd.
  • Sumitomo Pharma Co., Ltd.
  • Novartis Pharma K.K.
  • Bristol-Myers Squibb Company Ltd.
  • Janssen Pharmaceutical K.K
  • AstraZeneca Pharma Japan Ltd.
  • Pfizer Japan Inc.

第14章 戦略的推奨事項

第15章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Japan Cancer Therapeutics Market, By Value, In USD Billion, FY2017-FY2031F
  • Figure 2. Japan Cancer Therapeutics Market Share, By Applications, In USD Billion, FY2017-FY2031F
  • Figure 3. Japan Cancer Therapeutics Market Share, By Therapeutics, In USD Billion, FY2017-FY2031F
  • Figure 4. Japan Cancer Therapeutics Market Share, By Top Selling Drugs, In USD Billion, FY2017-FY2031F
  • Figure 5. Japan Cancer Therapeutics Market Share, By End-user, In USD Billion, FY2017-FY2031F
  • Figure 6. Japan Cancer Therapeutics Market Share, By Region, In USD Billion, FY2017-FY2031F
  • Figure 7. By Applications Map-Market Size (USD Billion) & Growth Rate (%), FY2023
  • Figure 8. By Therapeutics Map-Market Size (USD Billion) & Growth Rate (%), FY2023
  • Figure 9. By Top Selling Drugs Map-Market Size (USD Billion) & Growth Rate (%), FY2023
  • Figure 10. By End-user Map-Market Size (USD Billion) & Growth Rate (%), FY2023
  • Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2023
目次
Product Code: MX10463

Japan Cancer Therapeutics Market size was valued at USD 10.2 billion in FY2023, which is expected to reach USD 19.9 billion in FY2031, with a CAGR of 8.7% for the forecast period between FY2024 and FY2031. Several factors propel the Japan cancer therapeutics market forward, encompassing the growing incidence of cancer, heightened demand for cancer treatments, substantial government backing, a robust presence of pharmaceutical corporations, Japan's aging demographics, the increasing occurrence of lifestyle-related cancers, and the rising utilization of telemedicine and remote patient monitoring. These factors collectively contribute to the dynamic growth of Japan's cancer therapeutics market, offering cancer patients enhanced access to care while reducing the need for hospital or clinic visits.

The Japan cancer therapeutics market is leading the way in healthcare advancements, shaped by a convergence of significant factors that define its dynamic terrain. Among these factors, the escalating incidence of cancer within the nation emphasizes the pressing need for innovative therapeutic remedies. As Japan grapples with an aging population, cancer rates have surged, necessitating comprehensive approaches encompassing diagnosis, treatment, and patient care. Japan cancer therapeutics market is further driven by the increasing demand for effective cancer treatments. Patients and healthcare providers actively seek state-of-the-art therapies to combat the diverse spectrum of cancers affecting the populace.

The pivotal role played by the Japanese government is integral to the growth of Japan cancer therapeutics market. Through its policies, funding, and initiatives, it provides substantial support to advance cancer research, early detection methods, and treatment modalities. The presence of influential pharmaceutical companies, both domestic and international, significantly contribute to the market's vitality. These companies are at the forefront of pioneering research and development endeavors, bringing innovative therapies and treatment options to the forefront. Furthermore, the rising incidence of lifestyle-related cancers accentuates the need for personalized interventions and treatments. The adoption of telemedicine and remote patient monitoring is gaining momentum, revolutionizing cancer care delivery by offering accessible and convenient options for patients. In this dynamic landscape, the Japan cancer therapeutics market embodies a commitment to combating cancer and improving the well-being of those impacted by this formidable disease.

Increase in the Lifespan

Extended lifespans signify advancements in healthcare, lifestyle improvements, and societal conditions, and they entail a heightened susceptibility to cancer. Individuals accumulate greater exposure to risk factors like environmental toxins and genetic mutations with time. Consequently, the prevalence of cancer rises as people enjoy longer lives, contributing to the increased mortality rates. This increase in cancer-related deaths across the entire population can be ascribed to the burgeoning life expectancy, a prominent trend in Japan. This trend arises from the nation's rapidly aging demographic, characterized by a growing proportion of elderly citizens. In 2022, Japan achieved an impressive life expectancy of 84.91 years, representing a noteworthy 0.14% increment compared to the previous year. This substantial increase in life expectancy has led to a significant rise in the number of cancer cases, driving greater demand within Japan cancer therapeutics market.

Novel Cancer Therapies

Japanese scientists are leading in pioneering cancer therapy breakthroughs. Their inventive strategies aspire to transform the landscape of Japan cancer therapeutics market. These endeavors encompass innovative methods designed to pinpoint cancer cells with greater precision while mitigating the damage to surrounding healthy tissue. This can potentially diminish the typical side effects linked to existing therapies. By harnessing state-of-the-art technologies and scientific knowledge, Japan's research community is dedicating immense effort to enhance the efficacy and availability of cancer treatments. In doing so, they provide optimism for improved patient outcomes and a better global response to the battle against cancer. A novel approach, spearheaded by Katsunori Tanaka at Japan's RIKEN Cluster for Pioneering Research (CPR) and Hiromitsu Haba at the RIKEN Nishina Centre for Accelerator-Based Science (RNC), has been devised.

The techniques are effective for treating various types of cancer with reduced adverse effects compared to current methodologies. A proof-of-concept investigation publish ed on June 27, 2023, in the Journal of Chemical Science demonstrated that following a single injection of a compound engineered to emit minimal amounts of alpha radiation within cancer cells, tumors in mice exhibited nearly a threefold reduction in growth, leading to 100% survival. Importantly, this approach selectively targets cancer cells while preserving healthy tissue.

Government Initiatives

Japan's government has taken a leading role in promoting significant initiatives in the field of cancer research, which ultimately acts as a big support to Japan cancer therapeutics market. Recognizing the urgency of addressing cancer-related challenges among its populace, Japan has allocated substantial resources and exerted significant efforts to drive progress in this domain. These initiatives encompass a broad range of activities, including funding innovative research projects, facilitating collaboration between academic and medical institutions, and implementing national cancer control programs. The government's proactive approach to cancer research demonstrates its commitment to improving healthcare outcomes and improving its citizens' overall health and well-being. For example, in December 2022, the IAEA initiated the Rays of Hope Partnership in collaboration with 11 Japanese universities and institutions. This partnership aims to bolster cancer care across Asia and the Pacific, particularly in regions lacking access to radiotherapy or facing disparities in healthcare. Rays of Hope emphasizes a selected range of high-impact, cost-efficient, and sustainable interventions that align with each nation's specific healthcare needs and commitments.

Increasing Interest in Immunotherapy

Immunotherapies have witnessed a prominent increase in demand as a favored cancer treatment method, which is beneficial for Japan cancer therapeutics market. These therapies represent an innovative approach to combat cancer by harnessing the body's immune system. Several factors contribute to their rising appeal. To begin with, immunotherapies have exhibited impressive efficacy in specific cancer types, frequently yielding enduring and sustainable outcomes. Furthermore, the Japanese healthcare system's dedication to innovation, thorough clinical testing, and approval procedures have streamlined the integration of state-of-the-art immunotherapies into the healthcare market, enhancing patient access.

For example, in January 2022, the American multinational pharmaceutical company Bristol-Myers Squibb K.K. announced the approval of Abecma (idecabtagene vicleucel) by the Japan' s Ministry of Health, Labor and Welfare. Abecma is a chimeric antigen receptor (CAR) T cell immunotherapy directed towards B-cell maturation antigen (BCMA). The approval allows its use in treating adult patients grappling with relapsed or refractory (R/R) multiple myeloma.

Rising Cases of Lung Cancer

The alarming rise in lung cancer cases is leading to substantial growth in Japan cancer therapeutics market. Lung cancer is a prominent health concern in Japan, with a notable emphasis on METex14 metastatic non-small cell lung cancer (NSCLC). This variant of lung cancer, characterized by MET exon 14 skipping mutations, is overly aggressive and poses a significant threat to patients. Every year, around 3,000 individuals in Japan receive a diagnosis of METex14 metastatic NSCLC, underscoring the substantial impact of this disease on the population. Lung cancer is a prominent health concern in Japan, with a notable emphasis on METex14 metastatic non-small cell lung cancer (NSCLC).

For example, in June 2020, Novartis Pharma K.K. disclosed that Japan's Ministry of Health, Labor and Welfare (MHLW) approved Tabrecta. Tabrecta is an oral MET inhibitor designed to treat advanced and recurrent unresectable non-small cell lung cancer (NSCLC) with a specific genetic mutation known as MET exon 14 skipping (METex14). This approval extends to first-line and previously treated patients, irrespective of their prior treatment history.

Impact of COVID-19

The pandemic disrupted cancer care services in Japan, causing delays in diagnosis and treatment. Several factors contributed to this disruption, including strain on Japan's healthcare system, resulting in delayed cancer care services. Many individuals, including cancer patients, also hesitated to seek medical attention due to concerns about contracting COVID-19 in healthcare facilities. Consequently, the number of cancer diagnoses and treatments decreased during the initial stages of the pandemic in Japan. However, there has been significant improvement recently, with cancer care services returning to normalcy. The COVID-19 pande mic is anticipated to positively impact the Japanese cancer therapeutics market in the long term. This is because the pandemic has underscored the significance of early cancer detection and treatment. Consequently, more individuals are expected to engage in cancer screening initiatives and promptly seek medical assistance if they exhibit any cancer-related symptoms.

Key Players Landscape and Outlook

In Japan's cancer therapeutics market's dynamic landscape, collaboration is a fundamental driver of innovation. With an aging population and increasing cancer challenges, partnerships between pharmaceutical firms, research entities, and healthcare providers have gained paramount importance. These collaborative endeavors facilitate the creation of state-of-the-art therapies, innovative treatment strategies, and progress in cancer care. Within this competitive environment, cooperation plays a pivotal role in the relentless pursuit of enhanced treatments and better results for cancer patients in Japan.

For instance, in February 2022, Ono Pharmaceutical Co., Ltd., one of Japan's leading pharmaceutical firms, and Bristol-Myers Squibb K.K., an American multinational pharmaceutical company, jointly announced the signing of an outsourcing agreement with Prime Research Institute for Medical RWD, Inc. (based in Kyoto, Japan and referred to as "PRiME-R"). This collaboration aims to facilitate an industry-sponsored, large-scale, multi-institutional clinical research initiative focused on patients with gastric cancer receiving treatment with Opdivo (nivolumab) in combination with chemotherapy. The study will leverage PRiME-R's data input support system, "CyberOncology," designed to standardize, structure, manage, and integrate real-world data derived from routine cancer clinical practices.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of Covid-19 on Japan Cancer Therapeutics Market

4. Executive Summary

5. Japan Cancer Therapeutics Market Outlook, FY2017-FY2031F

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Application
    • 5.2.1. Lung Cancer
    • 5.2.2. Blood Cancer
    • 5.2.3. Colorectal Cancer
    • 5.2.4. Prostate Cancer
    • 5.2.5. Breast Cancer
    • 5.2.6. Cervical Cancer
    • 5.2.7. Glioblastoma
    • 5.2.8. Head & Neck Cancer
    • 5.2.9. Malignant Meningioma
    • 5.2.10. Mesothelioma
    • 5.2.11. Melanoma
    • 5.2.12. Others
  • 5.3. By Therapeutics
    • 5.3.1. Chemotherapy
    • 5.3.2. Targeted Therapy
    • 5.3.3. Immunotherapy
    • 5.3.4. Hormonal Therapy
    • 5.3.5. Other
  • 5.4. By Top Selling Drugs
    • 5.4.1. Revlimid
    • 5.4.2. Avastin
    • 5.4.3. Herceptin
    • 5.4.4. Rituxan
    • 5.4.5. Opdivo
    • 5.4.6. Gleevec
    • 5.4.7. Velcade
    • 5.4.8. Imbruvica
    • 5.4.9. Ibrance
    • 5.4.10. Zytiga
    • 5.4.11. Alimta
    • 5.4.12. Xtandi
    • 5.4.13. Tarceva
    • 5.4.14. Perjeta
    • 5.4.15. Temodar
    • 5.4.16. Others
  • 2.1. By End-user
    • 2.1.1. Hospitals
    • 2.1.2. Specialty Clinics
    • 2.1.3. Cancer & Radiation Therapy
  • 2.2. By Region
    • 2.2.1. North [Hokkaido and Tohoku]
    • 2.2.2. Central [Kanto and Chubu]
    • 2.2.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 2.3. By Company Market Share (%), FY2023

6. Market Mapping, FY2023

  • 6.1. By Application
  • 6.2. By Therapeutics
  • 6.3. By Top Selling Drugs
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Daiichi Sankyo Company, Ltd.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Takeda Pharmaceutical Company Ltd.
  • 13.3. Chugai Pharmaceutical Co., Ltd.
  • 13.4. Astellas Pharma Inc.
  • 13.5. Otsuka Pharmaceutical Co., Ltd.
  • 13.6. Eisai Co., Ltd.
  • 13.7. Shionogi & Co., Ltd.
  • 13.8. Kyowa Kirin Co., Ltd.
  • 13.9. Ono Pharmaceutical Co., Ltd.
  • 13.10. Sumitomo Pharma Co., Ltd.
  • 13.11. Novartis Pharma K.K.
  • 13.12. Bristol-Myers Squibb Company Ltd.
  • 13.13. Janssen Pharmaceutical K.K
  • 13.14. AstraZeneca Pharma Japan Ltd.
  • 13.15. Pfizer Japan Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer